The Medical Drug Market and its Reforms

  • Carine Milcent
Chapter

Abstract

China is the second largest pharmaceutical market in the world. This sector grew by 21.4% between 2002 and 2012. In OECD countries, spending on medical drugs accounted for approximately 17% of total health spending or 1.5% of gross domestic product (GDP) in 2009. That same year, spending on pharmaceutical products in China represented 43% of the total healthcare expenditure. Aware of the issue, the Chinese government has reacted. A limitation on the hospital mark-up on drugs has been implemented and a list of key drugs that are considered essential has been set up. Drugs on this list have to be accessible to everyone, with a regulated price to be kept as low as possible. To keep prices low, procurement is made through centralized bidding at provincial level, pharmaceutical companies delivering directly to medical facilities. Yet, in the field, the reality remains at times complex, with different ways to circumvent these constraints.

Keywords

Medical drug market The essential medicines list Over the counter (OTC) drugs Prescribed drugs 

Bibliography

  1. Barber, S., Baobin Huang, Budiono Santoso, Richard Laing, Valerie Paris, and Chunfu Wu, “The Reform of the Essential Medicines System in China: A Comprehensive Approach to Universal Coverage,” Journal of Global Health, Vol. 3 No. 1, June 2013.Google Scholar
  2. Ding, D., Q. Pan, L. Shan, C. Liu, L. Gao, Y. Hao, J. Song, N. Ning, Y. Cui, Y. Li, X. Qi, C. Liang, Q. Wu, and G. Liu, “Prescribing Patterns in Outpatient Clinics of Township Hospitals in China: A Comparative Study Before and After the 2009 Health System Reform,” International Journal of Environmental Resource of Public Health, Vol. 13, No. 7, 2016.Google Scholar
  3. Eggleston, K., L. Li, Q. Meng, M. Lindelow, and A. Wagstaff, “Health Service Delivery in China: A Literature Review,” Health Economics, Vol. 7, 2008, pp. 149–165.Google Scholar
  4. Institute for Healthcare Informatics—IMS, “Understanding the Role and Use of Essential Medicines Lists,” 2015.Google Scholar
  5. Kahler, Christine, “China’s Healthcare Reform: How Far Hat it Come?” China Business Review, 1 January 2011. http://www.chinabusinessreview.com/chinas-healthcare-reform-how-far-has-it-come/. Accessed September 2017.
  6. Li, Y., C. Ying, G. Sufang, P. Brant, L. Bin, and D. Hipgrave, “Evaluation, in Three Provinces, of the Introduction and Impact of China’s National Essential Medicines Scheme,” Bulletin of the World Health Organization, Vol. 91, 2013, pp. 184–194Google Scholar
  7. OECD, Value for Money in Health Spending, Paris, OECD Health Division, 2010.Google Scholar
  8. Reynolds, L., and M. McKee, “Factors Influencing Antibiotic Prescribing in China: An Exploratory Analysis,” Health Policy, Vol. 90, No. 1, 2009, pp. 32–36.Google Scholar
  9. Shekhar Kar, S., H. Sekhar Pradhan, and G. Prasad Mohanta, “Concept of Essential Medicines and Rational Use in Public Health,” Indian Journal Community Medicine, 2010.Google Scholar
  10. Song, Y., Y. Bian, and L. Li, “Current Perspectives on China’s National Essential Medicine System: Primary Care Provider and Patient Views,” BMC Health Services Research, Vol. 16, No. 30, 2016.Google Scholar
  11. Song, Y., Y. Bian, M. Petzold, L. Li, and A. Yin “The Impact of China’s National Essential Medicine System on Improving Rational Drug Use in Primary Health Care Facilities: An Empirical Study in Four Provinces,” BMC Health Services Research, Vol. 14, 2014a, p. 507. http://www.biomedcentral.com/1472-6963/14/507. Accessed September 2017.
  12. Song, Y., Y. Bian, M. Petzold, and A. Yin, “Effects of the National Essential Medicine System in Reducing Drug Prices: An Empirical Study in Four Chinese Provinces,” Journal of Pharmaceutical Policy and Practice React-text: 15, Vol. 7, No. 1, p.12, /react-text react-text: 18/react-text react-text: 19 September 2014b.Google Scholar
  13. Wang, L., E. Ma, and W. Xu, Comparative Analyses of China National &Twenty Two Selected Provincial Essential Medicines Lists to the WHO 2011 Model List, WHO, 2011.Google Scholar
  14. Wang, D., and X. Zhang, “The Selection of National Essential Medicines in China: Progress and the Way Forward,” Southern Medical Review, Vol. 4, 2011, pp. 22–28.Google Scholar
  15. Xiang Zhang, “More Measures Needed to Deepen Healthcare Reform in China: Vice Premier,” Xinhua English News, November 11.Google Scholar
  16. Yang, L., C. Liu, J.A. Ferrier, W. Zhou, and X. Zhang, “The Impact of the National Essential Medicines Policy on Prescribing Behaviors in Primary Care Facilities in Hubei Province of China,” Health Policy Plan, 2012.Google Scholar
  17. Yip, Winnie Chi-Man, William C. Hsiao, Wen Chhen, Shanlian Hu, Jin Ma, and Alan Maynard, “Early Appraisal of China’s Huge and Complex Health-Care Reforms,” The Lancet, Vol. 379, No. 9818, 2012, pp. 833–842.Google Scholar
  18. Zhang, S., W. Zhang, H. Zhou, H. Xu, Z. Qu, M. Guo, F. Wang, Y. Zhong, L. Gu, X. Liang, Z. Sa, X. Wang, and D. Tian, “How China’s New Health Reform Influences Village Doctors’ Income Structure: Evidence from a Qualitative Study in Six Counties in China,” Human Resources for Health, Vol. 13, No. 26, 2015.Google Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Carine Milcent
    • 1
  1. 1.CNRS and Paris School of Economics (PSE)ParisFrance

Personalised recommendations